Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14191 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Jan-Michel Heger und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and Univers…. Hauptthemen laut MEDLINE: Neoplasm, Residual, Lymphoma, Large B-Cell, Diffuse, Polymerase Chain Reaction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Else Kröner-Fresenius-Stiftung, Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Although several promising approaches for the treatment of relapsed/refractory diffuse large B‐cell lymphoma (rrDLBCL) have been approved recently, it remains unclear which patients will ultimately achieve long‐term responses. Circulating tumor (ct)DNA sequencing has emerged as a valuable tool to assess minimal residual disease (MRD). Correlations between MRD and outcomes have been shown in previously untreated DLBCL, but data on the repeated assessment of MRD in the dynamic course of rrDLBCL is limited. Here, we present an approach leveraging cost‐ and time‐sensitivity of digital droplet (dd)PCR to repeatedly assess MRD in rrDLBCL and present proof‐of‐principle for its ability to predict outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany.
- Cancer Center Cologne Essen, Cologne and Essen, Cologne, Germany.
- Cologne Lymphoma Working Group (CLWG), Cologne, Germany.
- Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
- West German Genome Center (WGGC), University of Cologne, Cologne, Germany.
- Department of Pathology, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany.
ORCID-Profile: Jan-Michel Heger
Förderung
- Else Kröner-Fresenius-Stiftung
- Deutsche Krebshilfe
- Deutsche Forschungsgemeinschaft
- Else Kröner-Fresenius Stiftung
- Novartis
- EKFS
Zitieren
APA
Heger, J. M., d'Hargues, Y., Kleinert, F., Mattlener, J., Weiss, J., Franzen, F., Becker, C., Becker, K., Gödel, P., Schmiel, M., Meinel, J., Flümann, R., Simon, F., Reinhardt, H. C., Borchmann, P., Borchmann, S., Balke-Want, H., Knittel, G., & von Tresckow, B. (2024). Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR. European Journal of Haematology. https://doi.org/10.1111/ejh.14191
Vancouver
Heger JM, d'Hargues Y, Kleinert F, Mattlener J, Weiss J, Franzen F, et al. Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR. European Journal of Haematology. 2024. doi:10.1111/ejh.14191
BibTeX
@article{Heger2024,
author = {Heger, Jan-Michel and d'Hargues, Yannick and Kleinert, Fanni and Mattlener, Julia and Weiss, Jonathan and Franzen, Fabian and Becker, Christian and Becker, Kerstin and Gödel, Philipp and Schmiel, Marcel and Meinel, Jörn and Flümann, Ruth and Simon, Florian and Reinhardt, H Christian and Borchmann, Peter and Borchmann, Sven and Balke-Want, Hyatt and Knittel, Gero and von Tresckow, Bastian},
title = {Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14191}
}
EUVIMED